Market research
OCD1.F ChromaDex Corporation
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 196M
- P/E ratio
- 15.5
- Analyst target
- 14.8
- Dividend yield
- Not available
- Beta
- 2.1
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US1710774076
- Market cap
- 196M
- P/E ratio
- 15.5
- Analyst target
- 14.8
- Dividend yield
- Not available
- Beta
- 2.1
About
About ChromaDex Corporation
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OCD1.F discussion.
5 years, 5 months ago
ChromaDex Corporation is currently in a long term uptrend where the price is trading 22.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 9.3.
ChromaDex Corporation's total revenue rose by 18.0% to $15M since the same quarter in the previous year.
Its net income has increased by 31.1% to $-6M since the same quarter in the previous year.
Finally, its free cash flow grew by 99.9% to $-1K since the same quarter in the previous year.
Based on the above factors, ChromaDex Corporation gets an overall score of 5/5.